Clinical and diagnostic difficulties in management of patients with laminopathies

Mutations in the LMNA gene cause developing of several phenotypes, both with isolated involvement of cardiac, muscle, adipose and bone tissues, and with their combination. The dominance of cardiovascular signs in the clinical performance and false clarity in nosology definition can cause underestimation of subclinical markers of other systems partaking. It leads to an incorrect interpretation of the true disease etiology, failure in genetic diagnostics, and untimely determination of the correct management and prognosis. The article presents clinical cases that demonstrate both the most typical manifestations of laminopathy and rare combinations of symptoms, which represent a certain diagnostic difficulty.

1. Stroud MJ. Linker of nucleoskeleton and cytoskeleton complex proteins in cardiomyopathy. Biophysical Reviews. 2018;10:1033–1051. doi:10.1007/s12551-018-0431-6.

2. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. Journal of the American college of cardiology. 2016;68:2299–2307. doi: 10.1016/j.jacc.2016.08.058.

3. Kärkkäinen S, Reissell E, Heliö T, et al. Novel mutations in the lamin A/C gene in heart transplant recipients with end stage dilated cardiomyopathy. Heart. 2006;92(4):524-6. doi:10.1136/hrt.2004.056721.

4. McNally E, Mestroni L. Circulation Research. 2017;121(7):731–748. doi:10.1161/CIRCRESAHA.116.309396.

5. Nishiuchi S, Makiyama T, Aiba T, et al. Gene-based risk stratification for cardiac disorders in LMNA mutation carriers. Circulation: cardiovascular genetics. 2017;10:e001603. doi:10.1161/CIRCGENETICS.116.001603.

6. Nakajima K, Aiba T, Makiyama T, et al. Clinical manifestations and long-term mortality in Lamin A/C mutation carriers from a Japanese multicenter registry. Circulation Journal. 2018;82(11):2707-2714. doi:10.1253/circj.CJ-18-0339.

7. Brauch KM, Chen LY, Olson TM. Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. Am J Cardiol. 2009;103(10):1426-28. doi:10.1016/j.amjcard.2009.01.354.

8. Paller M, Martin C, Pierpont ME. ESC Heart Failure. 2018;5:724–726. doi:10.1002/ehf2.12294.

9. Captur G, Arbustini E, Bonne G, et al. Heart. 2017;104(6):468-479. doi:10.1136/heartjnl-2017-312338.

10. Van Rijsingen I, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in Lamin A/C mutation carriers. Journal of the American College of Cardiology. 2012;59(5):493-50. doi:10.1016/j.jacc.2011.08.078.

11. Van Berlo JH, de Voogt WG, van der Kokoi, et al. Meta-analysis of clinical characteristic of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a hidh risc of sudden death. J Med Mol. 2005;83:79-81. doi:10.1007/s00109-004-0589-1.

12. Palojoki E, Kaartinen M, Kaaja R, et al. Pregnancy and childbirth in carriers of the lamin A/C-gene mutation. European Journal of Heart Failure. 2010;12:630–633. doi:10.1093/eurjhf/hfq059.